The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study
ConclusionsAlthough the benefit –risk profile for febuxostat is considered favorable for the treatment of hyperuricemia in certain patients with gout, real-world febuxostat utilization decreased during the study period, presumably in response to the label change.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
More News: Allopurinol | Cardiology | Cardiomyopathy | Cardiovascular | Databases & Libraries | Diabetes | Diabetes Mellitus | Endocrinology | Gout | Heart | Heart Disease | Heart Failure | Rheumatology | Study | USA Health | Warnings